On September 12, A-share indices turned negative in the afternoon session. At market close, the Shanghai Composite Index fell 0.12%, the Shenzhen Component Index dropped 0.43%, and the ChiNext Index declined 1.09%.
On the market front, cinema and film stocks surged in the afternoon, semiconductor sector posted significant gains, while non-ferrous metals, lab-grown diamonds, and memory chip concepts led the gainers; insurance, liquor, and banking sectors topped the decliners.
Cinema and Film Sector Surged Late in Session
In the afternoon, film stocks strengthened, with China Film Group Co.,Ltd. hitting the daily limit at market close, marking its third limit-up in six trading days. Previously, Golden Yi Cinema achieved three consecutive limit-ups, Happy Blue Ocean surged over 12%, while Wentou Holding, Beijing Enlight Media, Huayi Brothers Media, Bona Film Group, and China Vision Media Group followed suit.
On the news front, data recently disclosed by China's National Film Administration showed that China's mainland summer box office (June 1 to August 31, 2025) reached 11.966 billion yuan, with total viewership of 321 million, representing year-on-year increases of 2.76% and 12.75% respectively.
Analysts noted that the steady growth in summer box office performance, coupled with multiple blockbuster releases scheduled ahead, suggests that China's annual box office is expected to achieve year-on-year growth driven by quality content supply.
Semiconductor sector performed strongly, with VeriSilicon Holdings hitting the 20cm daily limit, while Advanced Micro-Fabrication Equipment Inc China and Beijing Vimicro Corporation gained over 10%.
On the news front, leading foundry TSMC recently reported revenue of NT$335.77 billion for August 2025, up 33.8% year-on-year and 3.9% month-on-month.
Guotou Securities noted that the global semiconductor industry maintained high prosperity in the first half of this year, with Chinese companies showing outstanding performance. Looking ahead to the second half, the industry will continue the dual development theme of "AI-driven + independent controllable."
Innovative drug concepts rebounded from lows, with Joinn Laboratories and Celegen hitting daily limits, Ydpharma rising over 10%, while Fujian Guangsheng Tang, Anlic Technology, and Celegen moved higher.
Titanium dioxide concepts fluctuated higher, with Zhenhua New Material rising over 5%, China National Gold Group Corporation gaining over 4%, while China Nuclear Titanium Dioxide and Jinpu Titanium Industry advanced.
Hong Kong Stock Pharmaceris-B Surged Nearly 120%
Hong Kong-listed Pharmaceris-B stock price soared in the afternoon session, rising nearly 120% intraday.
On the news front, Pharmaceris-B announced that its core product Tinengotinib (TT-00420) combined with fulvestrant for treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative or low expressing (HER2-) recurrent or metastatic breast cancer Phase II clinical trial received clinical default approval from China's National Medical Products Administration on September 10, 2025.
Kangfang Biopharmaceutical rose over 6%. On the news front, updated data from the first global multi-center Phase III clinical study HARMONi of Kangfang Biopharmaceutical's ivonescimab (AK112) was announced by overseas partner Summit Therapeutics at the World Lung Cancer Conference (WCLC 2025) plenary session chairman's symposium: the study successfully achieved its primary endpoint of progression-free survival (PFS).
Alibaba Hong Kong shares rose over 5%. On the news front, Alibaba's Tongyi Qianwen released its next-generation foundation model architecture Qwen3-Next and open-sourced the Qwen3-Next-80B-A3B series models based on this architecture. Compared to Qwen3's MoE model structure, this structure incorporates the following core improvements: hybrid attention mechanism, high-sparsity MoE structure, a series of training stability-friendly optimizations, and multi-token prediction mechanism to enhance inference efficiency.
Comments